Navigation Links
Novel Platform Technology for Allergy & Cancer Immunology Featured at Biotech Showcase 2016
Date:1/14/2016

HERSHEY, Pa. and ROCKVILLE, Md., Jan. 14, 2016 /PRNewswire/ -- A unique vaccine technology, with applications in allergy and cancer immunology, was the focus of yesterday's talk from Eric Winzer, CFO at Immunomic Therapeutics, Inc. (ITI) at the 2016 Biotech Showcase™.

Winzer shared that LAMP-Vax™ is uniquely designed to educate, direct and focus the immune system to create a strong immune memory response. By enhancing the antigen presentation to the immune system, the platform is expected to offer significant value for allergy and cancer vaccines in development. Following a deal made late last year, the Japanese firm Astellas Pharma is developing a pipeline of allergy therapies based on LAMP-Vax, allowing for ITI to focus on cancer immunology.

"Immunotherapy drugs will be treating 60% of cancers in the next 10 years and LAMP-Vax is potentially a critical enabling technology," noted Eric Winzer, CFO at Immunomic Therapeutics, Inc. "At Immunomix, we've developed a diverse and robust pipeline and LAMP-Vax could be a key part of the new era of effective cancer vaccine treatments."

About LAMP-Vax platform
The LAMP-Vax platform is a breakthrough technology that has the potential to fundamentally improve the use of vaccines across a wide variety of diseases.  LAMP-Vax is a next-generation DNA vaccine that stimulates an immune response against a particular protein by injecting the DNA encoding the protein rather than the protein itself.  However, unlike older, conventional DNA vaccines, LAMP-Vax includes the DNA sequence encoding Lysosomal Associated Membrane Protein (LAMP).  This allows DNA vaccines developed, based on the LAMP-Vax platform, to utilize the body's natural biochemistry to develop a more complete immune response compared to conventional DNA vaccines.  Unlike conventional DNA vaccines that primarily elicit a cytotoxic T cell immune response, vaccines developed using LAMP-Vax initiate a more complete immune response, including antibody production, cytokine release and critical immunological memory.  The ability to activate a complete immune response gives LAMP-Vax technology potential across a number of diseases, including cancer immunotherapy, allergy and infectious diseases.

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company dedicated to pioneering vaccines that transform lives.  Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI is developing next-generation vaccines based on patented LAMP Technology.  Its LAMP-Vax vaccine platform significantly increases the immune response to nucleic acid vaccines and simplifies vaccine design and delivery for safer, more cost-effective therapies.  LAMP constructs have been validated in human clinical trials for cancer and have been applied to targets like allergy, cancer and infectious diseases.  Immunomic Therapeutics' vision is to have regulatory approved products in pollen allergy, food allergy, cancer, and animal health. For information about Immunomic Therapeutics and LAMP Technology, visit www.immunomix.com.

 


'/>"/>
SOURCE Immunomic Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
2. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
3. The #1 Science Fiction Novel of 2011 (and NY Times Bestseller) Now Only $5.95
4. NuView Life Sciences and Thomas Jefferson University Sign Agreement for Exclusive Development and Commercialization Rights to Novel Prostate Cancer Diagnostic
5. Manipulating the Brain to Eliminate Fear or Restore Memories – Rudy Mazzocchi Releases the 2nd Novel in The EQUITY Series entitled "EQUITY of FEAR"
6. Samsung Thales signs Development Agreement with Novelda
7. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
8. U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios Novel Biologic Candidate for Pseudomonas aeruginosa
9. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
10. Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
11. Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2019)... FRANCISCO (PRWEB) , ... August 08, 2019 , ... ... Intelligent Virtual Agents for sales and service organizations, today announced that the ... Value Leadership Award for the IVA market . Inference will officially accept the ...
(Date:8/6/2019)... ... August 06, 2019 , ... Shoreline Biome, ... to the strain level, has announced partnerships with six international distributors. , ... and research organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New Zealand, Singapore, ...
(Date:8/4/2019)... ... ... Cirtec Medical Corporation, a strategic outsourcing partner for complex medical devices, including active implantables ... sq. ft. manufacturing facility in the Coyol free zone, located in Alajuela, Costa ... to be fully operational by the end of the year, will be the company’s ...
(Date:7/23/2019)... (PRWEB) , ... July 22, 2019 , ... ... biotech companies with best-in-class services in the fields of 3D tissue imaging ... machine learning , Visikol initially started back in 2013 as a products company. ...
Breaking Biology Technology:
(Date:8/29/2019)... ... , ... Lajollacooks4u has expanded its team as it gears up for a ... seen record growth in 2019, having hosted a multitude of team-building events and cooking ... visited the company’s La Jolla-based venue, and Lajollacooks4u has worked hard to accommodate the ...
(Date:8/27/2019)... ... 2019 , ... Shoreline Biome , a microbiome research company that develops ... as its CEO and Karen Woodward as its VP of Business Development. , ... its products and expand the company’s sales worldwide. , Prior to joining Shoreline Biome, ...
(Date:8/27/2019)... ... August 27, 2019 , ... Ambry Genetics ... genetic testing guidelines. In the largest cohort study of its kind, Ambry presents ... patients. , Clinicians use guidelines to inform decisions about which patients should ...
Breaking Biology News(10 mins):